Latest News

PROSPECT Study of Tirabrutinib in R/R PCNSL Completes Part A Enrollment
PROSPECT Study of Tirabrutinib in R/R PCNSL Completes Part A Enrollment

March 27th 2024

The first arm of the phase 2 PROSPECT study evaluating tirabrutinib for the treatment of relapsed/refractory primary central nervous system lymphoma has finished enrolling patients.

FDA Denies Approval of Odronextamab in DLBCL and Follicular Lymphoma
FDA Denies Approval of Odronextamab in DLBCL and Follicular Lymphoma

March 25th 2024

Fitting Loncastuximab Into the Current Landscape of R/R DLBCL
Fitting Loncastuximab Into the Current Landscape of R/R DLBCL

March 21st 2024

FDA Accepts BLA Resubmission of Denileukin Diftitox for R/R CTCL
FDA Accepts BLA Resubmission of Denileukin Diftitox for R/R CTCL

March 18th 2024

FDA Lifts Clinical Hold on Trial of NX-2127 in B-Cell Malignancies
FDA Lifts Clinical Hold on Trial of NX-2127 in B-Cell Malignancies

March 11th 2024

More News